PMID- 14566675
OWN - NLM
STAT- MEDLINE
DCOM- 20031212
LR  - 20061115
IS  - 0001-7868 (Print)
IS  - 0001-7868 (Linking)
VI  - 34
IP  - 4
DP  - 2003 Jul
TI  - The role of chromosome 8p22 deletion for predicting disease progression and 
      pathological staging in prostate cancer.
PG  - 247-9
AB  - The natural course of human prostate cancer is highly variable, and we still lack 
      reliable tools to predict the patient's outcome. Recent publications suggest that 
      the deletion of chromosome 8p22 has an important role for tumor progression in 
      prostate cancer. Totally, 97 patients (41 Japanese and 56 Swedish) were studied 
      to detect the status of chromosome 8p22 deletion by the fluorescence in situ 
      hybridization (FISH) technique. Seventy-seven underwent surgery (59 radical 
      prostatectomies or 18 lymph node dissections), and the specimens were prepared by 
      touch biopsy. Fine-needle aspiration biopsies (FNAB) were obtained from another 
      non-operative 20 cases. Disease progression was evaluated in 57 patients with a 
      median follow-up of 59 months. 8p22 deletions were detected in 58 (60 %) of all 
      cases. The frequency of 8p22 deletion did not significantly differ between 
      different preparations of specimens (touch biopsy vs. FNAB) as well as between 
      different races (Japanese vs. Swedish). Cases with more than pT3 tumors had a 
      significantly higher frequency of 8p22 deletion than those with pT2 (p < 0.01). 
      Multivariate analysis demonstrated that 8p22 deletion was the strongest parameter 
      to predict disease progression (hazard ratio = 5.75; p = 0.0001). Studies on 
      chromosomal deletions of 8p22 by the FISH technique may serve as a universal 
      genetic marker to optimize the treatment strategy in patients with prostate 
      cancer.
FAU - Matsuyama, H
AU  - Matsuyama H
AD  - Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi, 
      Japan.
FAU - Pan, Y
AU  - Pan Y
FAU - Oba, K
AU  - Oba K
FAU - Yoshihiro, S
AU  - Yoshihiro S
FAU - Matsuda, K
AU  - Matsuda K
FAU - Hagarth, L
AU  - Hagarth L
FAU - Kudren, D
AU  - Kudren D
FAU - Naito, K
AU  - Naito K
FAU - Bergerheim, U S R
AU  - Bergerheim US
FAU - Ekman, P
AU  - Ekman P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - Aktuelle Urol
JT  - Aktuelle Urologie
JID - 0421406
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymph Node Excision
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*genetics/surgery
MH  - Time Factors
EDAT- 2003/10/21 05:00
MHDA- 2003/12/13 05:00
CRDT- 2003/10/21 05:00
PHST- 2003/10/21 05:00 [pubmed]
PHST- 2003/12/13 05:00 [medline]
PHST- 2003/10/21 05:00 [entrez]
AID - 10.1055/s-2003-41607 [doi]
PST - ppublish
SO  - Aktuelle Urol. 2003 Jul;34(4):247-9. doi: 10.1055/s-2003-41607.